

Original Article



The Correlation between *IL-1β-C31T* Gene Polymorphism and Susceptibility to Breast Cancer

Nazan Eras ¹, Ferah Tuncel Daloglu ², Tahsin Çolak ³, Mehmet Guler ⁴, Etem Akbas ⁵

¹Department of Medical Genetics, Faculty of Medicine, Mersin University, Mersin, Turkey

²Department of Pathology, Faculty of Medicine, Mersin University, Mersin, Turkey

³Department of General Surgery, Faculty of Medicine, Mersin University, Mersin, Turkey

⁴Department of General Surgery, Medical Park Hospital, Antalya, Turkey

⁵Department of Medical Biology, Faculty of Medicine, Mersin University, Mersin, Turkey



Received: Nov 23, 2018

Accepted: May 9, 2019

Correspondence to

Nazan Eras

Department of Medical Genetics, Mersin University School of Medicine, 33343 Mersin, Turkey.

E-mail: nazaneras@gmail.com

© 2019 Korean Breast Cancer Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Nazan Eras

<https://orcid.org/0000-0001-5475-1684>

Ferah Tuncel Daloglu

<https://orcid.org/0000-0001-6506-9461>

Tahsin Çolak

<https://orcid.org/0000-0002-7253-5608>

Mehmet Guler

<https://orcid.org/0000-0001-7956-0892>

Etem Akbas

<https://orcid.org/0000-0001-7405-3277>

Conflict of Interest

The authors declare that they have no competing interests.

ABSTRACT

Purpose: Interleukin-1 beta (*IL-1β*), a pro-inflammatory cytokine, has been shown to influence breast cancer susceptibility. The relationship between its risk of breast cancer and *IL-1β-C31T* polymorphism has been demonstrated, but the results remain controversial. Therefore, our study aimed to investigate the correlation between the *IL-1β-C31T* gene polymorphism and susceptibility to breast cancer.

Methods: The genotype frequencies of *IL-1β-C31T* polymorphism were compared between 204 breast cancer cases and 210 controls using polymerase chain reaction and restriction fragment length polymorphism techniques. Further multivariate binary logistic regression analyses were used to assess the association between *IL-1β-C31T* polymorphism and breast cancer risk.

Results: The frequency of the *T* allele of *IL-1β-C31T* polymorphism in breast cancer cases was significantly higher than that in the controls (56.1% vs. 47.9%). The frequencies of genotypes *CC*, *CT*, and *TT* in the cases were 22.1%, 43.6%, and 34.3%, respectively, while in the control group they were 24.3%, 55.7%, and 20.0%, respectively. There was a significant difference between the prevalence of *TT* genotype in the 2 groups (adjusted odds ratio [OR], 2.06; 95% confidence interval [CI], 1.16–3.66; *p* = 0.014). Breast cancer risk increased in women with *TT* genotype, body mass index (BMI) ≥ 25 kg/m² (OR, 2.19; 95% CI, 1.09–4.36), late age at first birth (OR, 2.43; 95% CI, 1.29–4.56), postmenopausal status (OR, 3.15; 95% CI, 1.39–7.16), and negative smoking history (OR, 2.52; 95% CI, 1.32–4.82). Furthermore, increase in breast cancer risk among women diagnosed with invasive ductal carcinoma was associated with *CT/TT* genotypes (OR, 2.82; 95% CI, 1.38–5.76).

Conclusion: The *IL-1β-C31T* polymorphism affects breast cancer susceptibility, especially in women with late age at first birth, high BMI, postmenopausal status, negative smoking history, and invasive ductal carcinoma. Our study adds to the evidence about the importance of *IL-1β-C31T* polymorphism in breast cancer susceptibility.

Keywords: Breast neoplasms; Genetic susceptibility; Interleukin-1beta; Polymorphism, genetic

Author Contributions

Conceptualization: Çolak T; Data curation: Daloglu FT, Guler M; Formal analysis: Çolak T, Akbas E, Eras N; Investigation: Akbas E, Eras N; Methodology: Daloglu FT, Akbas E, Eras N; Project administration: Çolak T, Guler M, Eras N; Supervision: Çolak T, Akbas E; Validation: Guler M; Visualization: Akbas E; Writing - original draft: Eras N; Writing - review & editing: Eras N, Daloglu FT.

INTRODUCTION

Chronic inflammation resulting from oxidative stress has been considered as an important risk factor in the pathophysiology of various diseases, such as diabetes mellitus, rheumatoid arthritis, arteriosclerosis, Alzheimer's disease, and various cancers [1]. Inflammatory mediators, such as growth factors, cytokines, prostaglandins, reactive oxygen species, and reactive nitrogen species exist in cancer microenvironments and may lead to both genetic and epigenetic modifications resulting in the activation of oncogenes, the inactivation of tumor-suppressor genes, and the induction of chromosomal rearrangement, gene fusion, and gene amplification [2]. The interleukin (IL)-1 superfamily of cytokines comprises 7 molecules with agonist activity (IL α and β , IL-18, IL-33, IL-36 α , β , and γ), 3 receptor antagonists (IL-1Ra, IL-36Ra, and IL-38), and an anti-inflammatory cytokine (IL-37) [3]. The gene for IL-1 β is located at position 2q13-2q21 [4]. IL-1 β acts as a pro-inflammatory cytokine, and it is mainly produced by activated monocytes and macrophages [5]. In the development of breast cancer, IL-1 β upregulates cyclooxygenase-2, increases vascular endothelial growth factor expression in tumor cells, and participates in angiogenesis caused by chronic inflammation [6]. Furthermore, IL-1 β induces breast cancer cell proliferation by increasing aromatase activity that converts androgens to estrogen and by increasing steroid sulfatase activity, which converts conjugate estrogens to free-acting estrogens. Moreover, leptin and IL-1 β , which are pro-inflammatory adipocytokines, also have direct effect on breast epithelial cells to increase aromatase production and promote tumor growth, migration, and invasion through growth factors [7]. In breast cancer, a critical role of IL-1 β was established in previous studies [8-10]. These studies indicate that IL-1 β expression may combine with estrogen receptor-alpha to affect transcriptional regulation of breast cancer cells [8], which is significant in regulating protumorigenic events within the human breast tumor microenvironment [9], thereby increasing tumor aggressiveness [10].

Single nucleotide polymorphisms in genes encoding cytokines alter the binding affinity of cytokines to transcription factors and consequently change the level and functional activities of secreted cytokines. Three polymorphisms, including *IL-1 β -511 C > T* (rs16944), *IL-1 β -1464 G > C* (rs1143623), and *IL-1 β -31 C > T* (rs1143627), have been identified in the promoter region of *IL-1* gene. The *IL-1 β -511 C > T* polymorphism has been related with the promoter activity, and with increased risk of diseases such as cervical cancer [11] and gastric cancer [12]. Many epidemiologic studies have been focused on finding the relationships between *IL-1 β -G-1464C* polymorphism and various diseases such as renal cell carcinoma [13], type 2 diabetes mellitus [14], and non-small cell lung cancer [15]. The association of *IL-1 β -C31T* polymorphism and cancer has been studied in several cancers including non-small cell lung [16], hepatocellular carcinoma [17], and osteosarcoma [18]. Furthermore, many previous studies have been conducted to investigate the association between *IL-1 β -C31T* polymorphism and breast cancer risk in women. However, the data from these studies are not consistent [19-22]. To the best of our knowledge, there is only 1 study investigating the association of *IL-1 β -C31T* polymorphism with breast cancer in the Turkish population (126 cases and 110 controls) [20]. Therefore, in the present study, we sought to investigate whether *IL-1 β -C31T* polymorphism was related to the risk of breast cancer and whether there was a relationship between this polymorphism and demographic factors in the Turkish population.

METHODS

Study population

The study involved 204 women, between 26–76 years old who had confirmed histopathological and immunohistochemical diagnosis of primary breast carcinoma at the pathology Department of the Medical Faculty of Mersin University. Tumor types were retrieved from the pathology reports of these cases in the automation database. The controls consisted of 210 women ranging from 33–79 years old and 11.9% of the controls had a family history of breast cancer. They were selected from the population residing in the same region. Ethical Approval for the research study was obtained from the Ethical Committee of the Medical Faculty of Mersin University (IRB No. 11/08). All women provided an informed consent for this study. Information was collected based on a variety of factors, including family history of breast cancer, reproductive and menstrual history, age, and smoking status. Body mass index (BMI) for individuals participating in this study was calculated using the following formula: weight (kg)/height²(m²). In this study, we included breast cancer patients that were diagnosed following histopathological and immunohistochemical examinations. Therefore, patients that had other malignant tumor histories than breast cancer, undefined diagnosis, and male breast cancer patients were excluded from the study.

IL-1 β -C31T genotyping

The peripheral blood samples from women were transferred into an ethylenediaminetetraacetic acid tube, and DNA was extracted from the 414 blood samples using the phenol-chloroform method. All specimens were stored at –20°C until subsequent analysis. To determine the *IL-1 β -31* polymorphism, polymerase chain reaction (PCR) method was used with forward primer: 5'-AGA AGC TTC CAC CAA TAC T-3' and reverse primer: 5'-TAG CAC CTA GTT GTA AGG A-3' [20]. The 23 μ L PCR mixture contained about 50 pmol of each primer (forward and reverse), 30 ng of DNA, 125 mM of deoxynucleotide triphosphates, 500 U of Taq DNA polymerase (MBI Fermentas, Vilnius, Lithuania), 20 mM PCR buffer of (NH₄)₂SO₄, and 2.5mM of MgCl. The PCR amplification consisted of an initial melting step of 5 minutes at 94°C; followed by 25 cycles for 1 minute at 94°C, 1 minute at 54°C and 1 minute at 72°C, and a final elongation step for 5 minutes at 72°C [23]. The 240 bp PCR products were cut with *AluI* restriction enzyme (MBI Fermentas) by overnight incubation at 37°C, and electrophoresed in 3.0% agarose gel stained with ethidium bromide. The *IL-1 β T-31C* was digested into 3 expected results: *CC* genotype showing 1 band with 240 bp, *TT* genotype showing 2 bands with 138 bp and 103 bp, *CT* genotype showing 3 bands with 240 bp, 138 bp, and 103 bp. For quality control, the analyses on a random 10% of the samples were repeated to assess the reproducibility of results.

Statistical analysis

All calculations were performed using SPSS version 22 (IBM Corp., Armonk, USA). Student's *t*-test was used for comparison of numerical variables. The χ^2 test was used for categorical variables. Analyses were performed for breast cancer risk factors such as age (years), BMI (< 25, \geq 25 kg/m²), smoking status (never/ever), menopausal status (premenopausal and postmenopausal), and age at first pregnancy (< 20, \geq 20 years of age). Hardy–Weinberg equilibrium attained by the χ^2 test was used to evaluate the genetic distributions of participants. Furthermore, multivariate binary logistic regression analysis was performed to adjust the impact of the significant demographic characteristic of breast cancer while investigating the relationship between breast cancer and the *IL-1 β -C31T* polymorphism. *p*-value < 0.05 is accepted as statistically significant.

RESULTS

The selected demographic characteristics of subjects are shown in **Table 1**. There was no statistical difference in average of participants' age, age at first birth, age at menarche, or smoking status between control and case groups ($p > 0.05$). However, significant differences in BMI ($p = 0.001$), family history ($p = 0.031$), and age at menopause ($p = 0.001$) were detected between the studied groups.

Allele frequencies between breast cancer cases and control groups were compared through χ^2 test. The T allele frequency of *IL-1 β -31* gene increased in the breast cancer group versus control group (56.1% vs. 47.9%; odds ratio [OR]; 1.39; 95% confidence interval [CI], 1.06–1.83; $p = 0.017$). Additionally, multivariate binary logistic regression analysis showed statistically significant differences in genotype distributions between the breast cancer and control groups. Among the cases, the prevalence of CC, CT, and TT genotypes were 22.1%, 43.6%, and 34.3%, while they were 24.3%, 55.7%, and 20.0% among the controls, respectively. The associations of *IL-1 β -C31T* polymorphism with breast cancer risk were examined with stratification by body-mass index and family history. Compared with *IL-1 β -31* CC wild-type genotype, a significant increased risk was associated with TT homozygous

Table 1. The demographic characteristics of breast cancer cases and controls

Variable	Cases (n = 204)	Controls (n = 210)	p-value
Age (yr)*	50.38 \pm 10.53	49.04 \pm 8.21	0.147
Age at menopause (yr)*	49.24 \pm 4.68	46.68 \pm 4.44	0.001
Age at menarche (yr)*	13.23 \pm 1.3	13.39 \pm 1.12	0.175
BMI (kg/m ²)*	28.66 \pm 5.23	26.49 \pm 4.72	0.001
Age at first birth (yr)*	22.34 \pm 3.14	22.45 \pm 4.24	0.783
Family history [†]			0.031
No	164 (80.4)	185 (88.1)	
Yes	40 (19.6)	25 (11.9)	
Smoking status [†]			0.621
Never smokers	159 (77.9)	163 (77.6)	
Current smokers	45 (22.1)	47 (22.4)	
Histological types		-	-
Invasive ductal carcinoma	147 (72.0)		
Invasive papillary carcinoma	20 (9.8)		
Invasive mixed carcinoma	10 (4.9)		
Invasive lobular carcinoma	9 (4.4)		
Invasive cribriform carcinoma	3 (1.5)		
Medullary carcinoma	2 (1.0)		
Mucinous carcinoma	8 (3.9)		
Invasive micropapillary carcinoma	2 (1.0)		
Tubular carcinoma	3 (1.5)		

Data are shown as mean \pm standard deviation or number (%).

BMI = body mass index.

*Student t-test; [†]The χ^2 test.

Table 2. Comparison of the allele and genotype frequencies of *IL-1 β -C31T* in breast cancer cases and controls

<i>IL-1β-C31T</i>	Cases (n = 204)	Controls (n = 210)	OR (95% CI)	p-value
Genotype frequencies*				
CC genotype	45 (22.1)	51 (24.3)	1.0	-
CT genotype	89 (43.6)	117 (55.7)	0.88 (0.53–1.46)	0.862 [‡]
TT genotype	70 (34.3)	42 (20.0)	2.06 (1.16–3.66)	0.014 [‡]
Allele frequencies [†]				
C allele	179 (43.9)	219 (52.1)	-	-
T allele	229 (56.1)	201 (47.9)	1.39 (1.06–1.83)	0.017

OR = odds ratio; CI = confidence interval.

*Multivariate binary logistic regression analysis; [†]The χ^2 test; [‡]Adjusted for body-mass index and family history.

Table 3. OR values (95% CI) for breast cancer based on major risk factors and distribution of *IL-1β-C31T* genotypes (case/control)

Risk factors	CC genotype		CT genotype		TT genotype	
	OR (95% CI)	Case/control	OR (95% CI)	Case/control	OR (95% CI)	Case/control
Age(yr)*						
< 45	1.0 (ref.)	17/17	0.48 (0.21-1.12)	21/44	2.37 (0.82-6.89)	19/8
45-49	1.0 (ref.)	4/15	1.57 (0.44-5.65)	13/31	1.32 (0.31-5.61)	6/17
> 50	1.0 (ref.)	24/19	1.04 (0.51-2.14)	55/42	2.09 (0.92-4.76)	45/17
BMI(kg/m ²)*						
< 25	1.0 (ref.)	11/21	0.79 (0.32-1.95)	19/46	1.31 (0.47-3.61)	13/19
≥ 25	1.0 (ref.)	34/30	0.87 (0.48-1.57)	70/71	2.19 (1.09-4.36)	57/23
Age at first birth(yr)*						
< 20	1.0 (ref.)	6/9	0.61 (0.18-2.06)	13/32	0.90 (0.24-3.38)	9/15
≥ 20 or no birth	1.0 (ref.)	39/42	0.96 (0.56-1.64)	76/85	2.43 (1.29-4.56)	61/27
Menopausal status*						
Premenopausal	1.0 (ref.)	16/29	0.69 (0.33-1.46)	29/76	1.01 (0.42-2.37)	16/29
Postmenopausal	1.0 (ref.)	29/22	1.11 (0.56-2.19)	60/41	3.15 (1.39-7.16)	54/13
Smoking status*						
Never smokers	1.0 (ref.)	31/42	1.07 (0.62-1.88)	73/92	2.52 (1.32-4.82)	55/29
Current smokers	1.0 (ref.)	14/9	0.41 (0.14-1.17)	16/25	0.74 (0.24-2.27)	15/13

OR = odds ratio; CI = confidence interval; BMI = body mass index; OR = odds ratio; CI = confidence interval.

*The χ^2 test.

variant genotype (adjusted OR, 2.06; 95% CI, 1.16-3.66; $p = 0.014$), but it was not related with *CT* heterozygous genotype (OR, 0.88; 95% CI, 0.53-1.46; $p = 0.862$) (Table 2). We did not observe a deviation from Hardy-Weinberg equilibrium in the breast cancer or the control group. We found that the frequency of *IL-1β-31 CC* genotype in Hardy-Weinberg equilibrium in case group was $\chi^2 = 35.23$ ($p = 0.100$) while in the control group, it was $\chi^2 = 47.91$ ($p = 0.090$).

We analyzed the genotype distribution of *IL-1β-31* according to major breast cancer risk factors using the χ^2 test (Table 3). The *TT* genotype showed a 2.19-fold of increased breast cancer risk for obese women (BMI ≥ 25 kg/m²). Among women with late age at first birth, the *TT* genotype was associated with an increased breast cancer risk (OR, 2.43; 95% CI, 1.29-4.56) compared to *CT* and the *CC* genotype. Postmenopausal women with the *TT* genotype had a greater risk for breast cancer than those with *CT* and *CC* genotypes (OR, 3.15; 95% CI, 1.39-7.16). Never-smoking women with *TT* genotype had increased breast cancer risk compared to the current smoker (OR, 2.52; 95% CI, 1.32-4.82). However, in breast cancer subjects, the *TT* genotype was not associated with age factor.

Genotype distribution in relation to pathological types of breast cancer is shown in Table 4. In the χ^2 test, combined *CT/TT* genotypes were associated with a significantly increased risk of breast cancer in women with invasive ductal carcinoma (OR, 2.82; 95% CI, 1.38-5.76; $p = 0.004$) when compared to the *CC* genotype.

Table 4. Genotype distribution in relation to pathological types of breast cancer

Genotype	Invasive ductal carcinoma (n = 147)	Others (n = 57)	OR (95% CI)	p-value*
CC genotype	33	12	1.0	-
CT genotype	72	17	1.54 (0.66-3.59)	0.371
TT genotype	42	28	0.54 (0.24-1.23)	0.145
CT/TT genotype	114	45	2.82 (1.38-5.76)	0.004

OR = odds ratio; CI = confidence interval.

*The χ^2 test.

DISCUSSION

In the current study, we evaluated the possible influence of *IL-1 β -C31T* polymorphism within the promoter region of the *IL-1* gene, on the susceptibility of breast cancer. We also investigated whether major risk factors play a role in breast cancer development.

Allele frequency often varies substantially across population groups. Akisik and Dalay [20] found the frequency of *T* allele to be 55.4%, while we detected it as 47.9% in the Turkish population. Interestingly, the frequency of *T* allele in our control group is similar to that found in the Asian population from Korea (0.509) [24]. In the study of Liu et al. [22], *T* allele frequency was found as 0.541 in Asian population from China, which was similar to that reported in a Turkish population [20]. Previously, *T* allele frequency for this polymorphism in Asian population from Japan was reported to be 0.849 [19], which is significantly higher than that in other Asian populations including Chinese [22] and Koreans [24]. As given above, the distribution of genotype frequencies for *IL-1 β -C31T* polymorphism is different in individuals from different geographical regions. These differences in genotype distribution in various studies may be due to the small sample size.

The inflammasome is a multiprotein oligomer that activates pro-inflammatory cytokines including IL-18 and IL-1 β [25]. IL-1 β could enhance the production of chemokines, adhesion molecules, and prostaglandin. The increased expression may initiate an inflammatory cascade, such as cell chemotaxis, angiogenesis, and adhesiveness, which then cause cancer-associated inflammation [26]. Several studies have been conducted based on this close association between IL-1 β levels and invasiveness, aggressiveness, and high tumor grade of breast cancer [27-29]. A study showed that IL-1 β was present in 90% of invasive breast carcinomas, and it was suggested that elevated levels of IL-1 β were associated with tumor invasiveness and tumor aggressiveness [10]. Another study indicated that grade III tumors had higher IL-1 β expression levels compared to grade I and II tumors, and macrophage inflammatory protein-1 β was found to be associated with inflammation [28]. Kurtzman et al. [29] demonstrated that IL-1 β accumulated in tumor microenvironment, which might play an important role in regulating the growth and progression of breast tumor. IL-1 β found together with estrogen receptor- α was detected to increase gene expression with an estrogen responsive element in breast cancer cells [8].

To date, many epidemiological studies have evaluated the polymorphism of the *IL-1 β* gene with the risk of cancer such as cervical [11], gastric [12], and non-small cell lung cancer [15]. Several studies have focused on the association between the *IL-1 β -C31T* polymorphism and breast cancer risk. However, the findings of earlier studies are conflicting. Ito et al. [19] showed the protective role of *TT* genotype (*IL-1 β -C31T* rs1143627) against breast cancer onset in Japanese population (age-adjusted OR, 0.58; 95% CI, 0.32–1.02). A meta-analysis conducted in 2010, which included 8 case-control studies, concluded that *CC* genotype was associated with 1.37-fold increase in breast cancer risk [21]. Furthermore, Liu et al. [22] observed a positive relationship between *IL-1 β -31CC* genotype and breast cancer risk (adjusted OR, 1.72; 95% CI, 1.16–2.54). However, we observed a stronger relationship between the *IL-1 β -31TT* genotype and breast cancer risk (adjusted OR, 2.06; 95% CI, 1.16–3.66; $p = 0.014$). Two studies on the contrary, found that there was no difference in the distribution of genotypes between breast cancer cases and controls [20,24].

Previous studies have identified the risk factors that increase breast cancer risk. Major risk factors comprise age, age at first birth, menopausal status, BMI, and smoking status. Liu et al. [22] found 1.74-fold (95% CI, 1.13–2.67) increased risk of breast cancer in older women with *CT/CC* genotypes; however, our findings did not show any correlation between *TT* genotype and late age. In this study, we found an association between breast cancer risk and *TT* genotype among women with late age at first birth. In contrast, Liu et al. [22] did not observe association between *IL-1 β -31TC/CC* genotypes and early age first birth. In this study, *TT* genotype was associated with increased breast cancer risk in postmenopausal women. However, a case-control study showed that *IL-1 β -31CT/CC* variant genotypes were associated with increased breast cancer risk in postmenopausal Chinese women (adjusted OR, 1.56; 95% CI, 1.00–2.42) [22]. However, in subgroup analyses of menopausal status, *IL-1 β -31CT/CC* variant genotypes showed a preventive effect among postmenopausal women [19]. On the contrary, another study showed no significant modification of ORs for *CC* genotype by menopausal status [24]. In the current study, women who have *TT* genotype with BMI ≥ 25 kg/m² had a statistically significant 2.19-fold increased risk for developing breast cancer. Ito et al. [19] did not demonstrate any significant association between *TT* genotype and BMI ≥ 22 kg/m² in Japanese case-control study. We also detected that never smokers having *TT* genotype had an elevated risk of breast cancer. This may be because the smoking affected the metabolism of estradiol, leading to enhanced formation of the inactive catechol estrogens [30]. Moreover, for *IL-1 β -31CT/TT* variant genotype carriers, we observed a 2.82-fold increase in breast cancer risk associated with women diagnosed with invasive ductal carcinoma. To the best of our knowledge, our study is the first to evaluate the relationship between the genotypes of *IL-1 β -C31T* polymorphism and pathologic types of breast cancer.

In conclusion, we observed that a significantly increased risk of breast cancer was associated with *IL-1 β -C31T* polymorphism. Furthermore, we found that *IL-1 β -C31T* polymorphism might contribute to the development of breast cancer in women with: BMI ≥ 25 kg/m², late age at first birth, postmenopausal status, negative smoking history, and invasive ductal carcinoma. In future studies, these findings may elucidate the potential role of *IL-1 β* gene product, known as an inflammatory cytokine, in breast cancer development. However, genetic polymorphisms may vary among different ethnic groups and further studies including larger sample sizes of different ethnic groups are required to examine the association between *IL-1 β -C31T* polymorphism and breast cancer.

ACKNOWLEDGMENTS

The authors thank Seval KUL for assistance with statistical analysis.

REFERENCES

1. Rajendran P, Chen YF, Chen YF, Chung LC, Tamilselvi S, Shen CY, et al. The multifaceted link between inflammation and human diseases. *J Cell Physiol* 2018;233:6458-71.
[PUBMED](#) | [CROSSREF](#)
2. Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. *Front Immunol* 2012;2:98.
[PUBMED](#) | [CROSSREF](#)
3. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. *Immunity* 2013;39:1003-18.
[PUBMED](#) | [CROSSREF](#)

4. Webb AC, Collins KL, Auron PE, Eddy RL, Nakai H, Byers MG, et al. Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2. *Lymphokine Res* 1986;5:77-85.
[PUBMED](#)
5. Xu J, Yin Z, Cao S, Gao W, Liu L, Yin Y, et al. Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. *PLoS One* 2013;8:e63654.
[PUBMED](#) | [CROSSREF](#)
6. Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. *J Interferon Cytokine Res* 2015;35:1-16.
[PUBMED](#) | [CROSSREF](#)
7. Perrier S, Caldefie-Chézet F, Vasson MP. IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. *FEBS Lett* 2009;583:259-65.
[PUBMED](#) | [CROSSREF](#)
8. Speirs V, Kerin MJ, Newton CJ, Walton DS, Green AR, Desai SB, et al. Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. *Int J Oncol* 1999;15:1251-4.
[PUBMED](#)
9. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, et al. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. *Cancer Invest* 2000;18:293-302.
[PUBMED](#) | [CROSSREF](#)
10. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, et al. Expression of interleukin-1beta in human breast carcinoma. *Cancer* 1997;80:421-34.
[PUBMED](#) | [CROSSREF](#)
11. Lee YH, Song GG. A meta-analysis of the association between CTLA-4 +49 A/G, -318 C/T, and IL-1 polymorphisms and susceptibility to cervical cancer. *Neoplasma* 2014;61:481-90.
[PUBMED](#) | [CROSSREF](#)
12. Chen B, Luo MX, Zhou X, Lv Y, Su GQ. Correlation between interleukin-1 β -511 C/T polymorphism and gastric cancer in Chinese populations: a meta-analysis. *Med Sci Monit* 2016;22:1742-50.
[PUBMED](#) | [CROSSREF](#)
13. Wang F, Zhang Y, Wang S, Zhang Y, Wu D, Zhang C, et al. *IL1* genes polymorphism and the risk of renal cell carcinoma in Chinese Han population. *Oncotarget* 2017;8:56021-9.
[PUBMED](#)
14. Xiao D, Zhang SM, Li X, Yin JY, Gong WJ, Zheng Y, et al. IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowering efficacy of metformin in Chinese overweight or obese type 2 diabetes mellitus patients. *Pharmacogenomics* 2015;16:1621-9.
[PUBMED](#) | [CROSSREF](#)
15. Pérez-Ramírez C, Cañadas-Garre M, Alnatsa A, Molina MÁ, Robles AI, Villar E, et al. Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. *Surg Oncol* 2017;26:278-85.
[PUBMED](#) | [CROSSREF](#)
16. Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A. Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. *Int J Cancer* 2004;109:353-6.
[PUBMED](#) | [CROSSREF](#)
17. Tak KH, Yu GI, Lee MY, Shin DH. Association between polymorphisms of interleukin 1 family genes and hepatocellular carcinoma. *Med Sci Monit* 2018;24:3488-95.
[PUBMED](#) | [CROSSREF](#)
18. He Y, Liang X, Meng C, Shao Z, Gao Y, Wu Q, et al. Genetic polymorphisms of interleukin-1 beta and osteosarcoma risk. *Int Orthop* 2014;38:1671-6.
[PUBMED](#) | [CROSSREF](#)
19. Ito LS, Iwata H, Hamajima N, Saito T, Matsuo K, Mizutani M, et al. Significant reduction in breast cancer risk for Japanese women with interleukin 1B -31 *CT/TT* relative to *CC* genotype. *Jpn J Clin Oncol* 2002;32:398-402.
[PUBMED](#) | [CROSSREF](#)
20. Akisik E, Dalay N. Functional polymorphism of thymidylate synthase, but not of the *COMT* and *IL-1B* genes, is associated with breast cancer. *J Clin Lab Anal* 2007;21:97-102.
[PUBMED](#) | [CROSSREF](#)
21. Liu X, Wang Z, Yu J, Lei G, Wang S. Three polymorphisms in interleukin-1 β gene and risk for breast cancer: a meta-analysis. *Breast Cancer Res Treat* 2010;124:821-5.
[PUBMED](#) | [CROSSREF](#)
22. Liu J, Zhai X, Jin G, Hu Z, Wang S, Wang X, et al. Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population. *Int J Cancer* 2006;118:2554-8.
[PUBMED](#) | [CROSSREF](#)

23. Hamajima N, Saito T, Matsuo K, Kozaki K, Takahashi T, Tajima K. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. *Jpn J Cancer Res* 2000;91:865-8.
[PUBMED](#) | [CROSSREF](#)
24. Lee KM, Park SK, Hamajima N, Tajima K, Choi JY, Noh DY, et al. Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women. *Breast Cancer Res Treat* 2006;96:197-202.
[PUBMED](#) | [CROSSREF](#)
25. Kantono M, Guo B. Inflammasomes and cancer: the dynamic role of the inflammasome in tumor development. *Front Immunol* 2017;8:1132.
[PUBMED](#) | [CROSSREF](#)
26. Idris A, Ghazali NB, Koh D. Interleukin 1 β -A potential salivary biomarker for cancer progression? *Biomark Cancer* 2015;7:25-9.
[PUBMED](#) | [CROSSREF](#)
27. Escobar P, Bouclier C, Serret J, Bièche I, Brigitte M, Caicedo A, et al. IL-1 β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production. *Oncotarget* 2015;6:29034-47.
[PUBMED](#) | [CROSSREF](#)
28. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. *Breast Cancer Res* 2007;9:R15.
[PUBMED](#) | [CROSSREF](#)
29. Kurtzman SH, Anderson KH, Wang Y, Miller LJ, Renna M, Stankus M, et al. Cytokines in human breast cancer: IL-1alpha and IL-1beta expression. *Oncol Rep* 1999;6:65-70.
[PUBMED](#)
30. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. *Am J Obstet Gynecol* 1990;162:502-14.
[PUBMED](#) | [CROSSREF](#)